In this discussion, Christoph Correll, MD, professor of psychiatry at the Zucker School of Medicine, delves into the groundbreaking FDA approval of xanomeline/tropsium chloride, a novel treatment for schizophrenia that moves beyond...
In this discussion, Christoph Correll, MD, professor of psychiatry at the Zucker School of Medicine, delves into the groundbreaking FDA approval of xanomeline/tropsium chloride, a novel treatment for schizophrenia that moves beyond...
In this video, Steven Chan, MD, MBA, FAPA, FAMIA, Psych Congress Steering Committee, explains some of the barriers that virtual clinicians should anticipate when weighing digital therapeutic options for major depressive disorder (MDD)...
In this video, Steven Chan, MD, MBA, FAPA, FAMIA, Psych Congress Steering Committee, explains some of the barriers that virtual clinicians should anticipate when weighing digital therapeutic options for major depressive disorder (MDD)...
What role do long-acting injectables (LAIs) play in improving long-term outcomes for patients with schizophrenia? In this discussion, Brooke Kempf, PMHNP-BC, highlights the benefits of early LAI initiation, from reducing relapse rates and...
What role do long-acting injectables (LAIs) play in improving long-term outcomes for patients with schizophrenia? In this discussion, Brooke Kempf, PMHNP-BC, highlights the benefits of early LAI initiation, from reducing relapse rates and...
In this video, Andrew Penn, PMHNP-BC, NP, CNS, MS, RN offers some key clinical takeaways from his session on deprescribing and how it even has a place when treating patients living with serious mental illness like schizophrenia.
In this video, Andrew Penn, PMHNP-BC, NP, CNS, MS, RN offers some key clinical takeaways from his session on deprescribing and how it even has a place when treating patients living with serious mental illness like schizophrenia.
Rebecca Barbee, MSPAS, PA-C, CAQ-Psych, explains the differences between dystonia, akathisia, drug-induced Parkinsonism, and tardive dyskinesia, as well as the different management approaches for each.
Rebecca Barbee, MSPAS, PA-C, CAQ-Psych, explains the differences between dystonia, akathisia, drug-induced Parkinsonism, and tardive dyskinesia, as well as the different management approaches for each.
Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN
Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
